NHS Branded Medicines Framework for North of England and Midlands and East - 1 March 2024

A Contract Award Notice
by NHS ENGLAND

Source
Contracts Finder
Type
Framework (Products)
Duration
2.5 year
Value
£580M
Sector
HEALTH
Published
26 Feb 2024
Delivery
01 Mar 2024 to 31 Aug 2026
Deadline
22 Nov 2023 13:00

Concepts

Location

Geochart for 1 buyers and 39 suppliers

1 buyer

39 suppliers

Description

Project Title: NHS Branded Medicines Framework for North of England and Midlands and East - 1 March 2024 Offer reference number: CM/PHR/22/5678 CM/PHR/22/5678/01 - NHS Framework for NORTH OF ENGLAND Branded Medicines - Tranche B. Period of framework: 1 March 2024 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. CM/PHR/22/5678/02 - NHS Framework for NORTH OF ENGLAND Branded Medicines (to transition to Tranche B) Period of framework: 1 March 2024 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. CM/PHR/22/5678/03 - NHS Framework for MIDLANDS AND EAST of England Branded Medicines - Tranche A. Period of framework: 1 March 2024 to 31 August 2026 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months CM/PHR/22/5678/04 - NHS Framework for MIDLANDS AND EAST of England Branded Medicines (to transition to Tranche B). Period of framework: 1 March 2024 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months

Award Detail

1 Zentiva Pharma (London)
  • Value: £688,010,000
2 Glaxosmithkline (London)
  • Value: £688,010,000
3 Celltrion Healthcare (Slough)
  • Value: £688,010,000
4 Biogen (Maidenhead)
  • Value: £688,010,000
5 Kent Pharma (Ashford)
  • Value: £688,010,000
6 Amgen (Cambridge)
  • Value: £688,010,000
7 Merck Sharpe & Dohme (London)
  • Value: £688,010,000
8 Accord (Barnstaple)
  • Value: £688,010,000
9 Neon Healthcare (Hertford)
  • Value: £688,010,000
10 Drreddys Laboratories (Cambridge)
  • Value: £688,010,000
11 Pfizer (Sandwich)
  • Value: £688,010,000
12 Bayer (Reading)
  • Value: £688,010,000
13 Sandoz (Camberley)
  • Value: £688,010,000
14 Aventis Pharma (Reading)
  • Value: £688,010,000
15 Vifor Pharma (London)
  • Value: £688,010,000
16 Chugai Pharma (London)
  • Value: £688,010,000
17 Sun Pharma (Uxbridge)
  • Value: £688,010,000
18 Sobi Swedish Orphan Biovitrum (Great Abington)
  • Value: £688,010,000
19 Mylan (Hatfield)
  • Value: £688,010,000
20 Galapagos Biotech (Cambridge)
  • Value: £688,010,000
21 Abbvie (Maidenhead)
  • Value: £688,010,000
22 Thornton & Ross (Huddersfield)
  • Value: £688,010,000
23 Merck Serono (Feltham)
  • Value: £688,010,000
24 Astrazeneca (London)
  • Value: £688,010,000
25 Janssen Cilag (Highwycombe)
  • Value: £688,010,000
26 Eli Lilly (Basingstoke)
  • Value: £688,010,000
27 Roche Products (Welwyn Garden City)
  • Value: £688,010,000
28 Ipsen (Slough)
  • Value: £688,010,000
29 Organon Pharmaceuticals (London)
  • Value: £688,010,000
30 Almirall (Uxbridge)
  • Value: £688,010,000
31 Merz (Hemel Hempstead)
  • Value: £688,010,000
32 Napp Pharmaceuticals (Cambridge)
  • Value: £688,010,000
33 CST Pharma (Walsall)
  • Value: £688,010,000
34 Pharmacosmos (Reading)
  • Value: £688,010,000
35 Orifarm (Hemel Hempstead)
  • Value: £688,010,000
36 Teva (Castleford)
  • Value: £688,010,000
37 Novo Nordisk (Gatwick)
  • Value: £688,010,000
38 Novartis Pharmaceuticals (London)
  • Value: £688,010,000
39 Gedeon Richter (London)
  • Value: £688,010,000

CPV Codes

  • 33600000 - Pharmaceutical products

Indicators

  • Contract is suitable for SMEs.

Other Information

FTS-031292-2023 OPPORTUNITY NOTICE - NHS Branded Medicines Framework for North of England and Midlands and East - 1 March 2024 FTS-031292-2023 OPPORTUNITY NOTICE - NHS Branded Medicines Framework for North of England and Midlands and East - 1 March 2024.pdf Document No.10 - Pharmacy Purchasing Points CM_PHR_22_5678 Document No.10 - Pharmacy Purchasing Points CM_PHR_22_5678.xls Transparency Award Schedule - CM-PHR-22-5678-04 Transparency Award Schedule - CM-PHR-22-5678-04.pdf Transparency Award Schedule - CM-PHR-22-5678-03 Transparency Award Schedule - CM-PHR-22-5678-03.pdf Transparency Award Schedule - CM-PHR-22-5678-01 Transparency Award Schedule - CM-PHR-22-5678-01.pdf CMPHR225678 - Parties Appointed to the framework - Branded NOFE & MAE Tranches CMPHR225678 - Parties Appointed to the framework - Branded NOFE & MAE Tranches.xlsx Document No. 03 - Framework Agreement and Terms and Conditions CM_PHR_22_5678 Document No. 03 - Framework Agreement and Terms and Conditions CM_PHR_22_5678.docx Transparency Award Schedule - CM-PHR-22-5678-02 Transparency Award Schedule - CM-PHR-22-5678-02.pdf

Reference

Domains